Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.

doi:10.1016/j.atherosclerosis.2020.01.031

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.

Atherosclerosis - 1 Apr 2020

Luirink Ilse K, Hutten Barbara A, Greber-Platzer Susanne, Kolovou Genovefa D, Dann Eldad J, de Ferranti Sarah D, Taylan Christina, Bruckert Eric, Saheb Samir, Oh Jun, Driemeyer Joenna, Farnier Michel, Pape Lars, Schmitt Claus P, Novoa Francisco J, Maeser Martin, Masana Luis, Shahrani Awad, Wiegman Albert, Groothoff Jaap W

Abstract excerpt

BACKGROUND AND AIMS: Homozygous familial hypercholesterolemia (hoFH) may cause life-threatening atherosclerotic cardiovascular disease in childhood. Lipoprotein apheresis (LA) is considered a pivotal treatment option, but data on its efficacy, safety and optimal performance are limited. We therefore established an international registry on the execution and outcomes of LA in HoFH children. Here we report LA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Component Removal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Cholesterol, LDL

Share to Down-Regulation

Share to Heart Disease Risk Factors

Share to Hyperlipoproteinemia Type II

Share to Registries

Share to Xanthomatosis

Source

Open in PubMed

Identifiers

PMID: 32199148
DOI: 10.1016/j.atherosclerosis.2020.01.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.PMID 32199148Read ↗

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPNSemantic proximity Read ↗

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.Semantic proximity Read ↗

Lipoprotein Apheresis: An Established Therapeutic Modality for Homozygous Familial Hypercholesterolemia Patients Refractory to PCSK9 Inhibitors: A Case Report and Literature ReviewSemantic proximity Read ↗

A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).Semantic proximity Read ↗

Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.Semantic proximity Read ↗

Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.Semantic proximity Read ↗

Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents.Semantic proximity Read ↗

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.Semantic proximity Read ↗

Severe hypercholesterolemia in a pediatric cohort: Familial homozygous and autosomal recessive hypercholesterolemia.Semantic proximity Read ↗

Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry.Semantic proximity Read ↗

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.Semantic proximity Read ↗

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.